Juliette Saillard

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Florence Ader, Maude Bouscambert‐Duchamp, Maya Hites et al. · The Lancet Infectious Diseases · 2021 · 338 citations · Full text

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

François Raffi, Abdel G. Babiker, Laura Richert et al. · The Lancet · 2014 · 172 citations

Treatment And Prevention, Antiviral Drug Development, Clinical Trials +10

Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial

Pierre de Truchis, Lambert Assoumou, Roland Landman et al. · Journal of Antimicrobial Chemotherapy · 2017 · 33 citations · Full text

Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group

Alpha Diallo, Marius Trøseid, Victoria Charlotte Simensen et al. · Clinical Microbiology and Infection · 2021 · 24 citations · Full text

Clinical Trial Implementation, Global Health, Global Health Crisis +7

Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial

Florence Ader, Nathan Peiffer‐Smadja, Julien Poissy et al. · 2021 · 15 citations · Full text

Hydroxychloroquine Efficacy, Pharmacotherapy, Covid-19 Epidemiology +16